<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Secondary causes of dyslipidemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Secondary causes of dyslipidemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Secondary causes of dyslipidemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In many patients, hyperlipidemia is caused by some underlying "nonlipid" etiology rather than a primary disorder of lipoprotein metabolism. The secondary causes of dyslipidemia will be reviewed briefly here  (<a class="graphic graphic_table graphicRef114879" href="/z/d/graphic/114879.html" rel="external">table 1</a>).</p><p>Primary lipid disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a> and  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p class="headingAnchor" id="H2852593825"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Dyslipidemia due to secondary causes is common. In a cohort of 824 new patients referred to a lipid clinic at an academic medical center in the United States, 28 percent had one or more potential causes of secondary dyslipidemia [<a href="#rid1">1</a>]. The most common conditions that were felt to be contributing to dyslipidemia were excessive alcohol intake (10 percent) and uncontrolled diabetes mellitus (8 percent).</p><p class="headingAnchor" id="H3718840870"><span class="h1">DISEASE ASSOCIATIONS</span></p><p class="headingAnchor" id="H2"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>Hyperlipidemia in association with insulin resistance is common in patients with type 2 diabetes mellitus [<a href="#rid2">2,3</a>]. Insulin resistance and the ensuing hyperinsulinemia are associated with hypertriglyceridemia, increased low-density lipoprotein (LDL), and low serum high-density lipoprotein (HDL) cholesterol concentrations. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Lipid management'</a>.)</p><p>The lipoprotein abnormalities are related to the severity of the insulin resistance. A study that measured insulin sensitivity using a euglycemic clamp in patients with and without type 2 diabetes mellitus found that greater insulin resistance was associated with larger very low-density lipoprotein (VLDL) particle size, smaller LDL particle size, and smaller HDL particle size [<a href="#rid4">4</a>]. Additionally, the number of VLDL, intermediate-density lipoprotein (IDL), and LDL particles increase with increasing insulin resistance, while HDL particle concentration decreases.</p><p>Hypertriglyceridemia results both from increased substrate availability (glucose and free fatty acids) and from decreased lipolysis of VLDL triglyceride. Nicotinic acid can partially correct these disturbances but at the potential expense of increased insulin resistance and worse glycemic control. In one study, for example, nicotinic acid administration led to a 21 percent rise in hemoglobin A1c values [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Cholestatic liver disease</span><span class="headingEndMark"> — </span>Primary biliary cholangitis and similar disorders may be accompanied by marked hypercholesterolemia that results from an accumulation of lipoprotein-X and/or lipoprotein-Z [<a href="#rid5">5</a>]. Clinical stigmata include xanthomata striata palmare that may appear when the serum cholesterol concentration is 1400 mg/dL (36 mmol/L) or higher. Xanthomata appear on the extremities as well. Marked elevations in lipoprotein X has been associated with the hyperviscosity syndrome [<a href="#rid5">5</a>], but no clear association with coronary heart disease has been established [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p class="headingAnchor" id="H2693873724"><span class="h2">Renal diseases</span></p><p class="headingAnchor" id="H4"><span class="h3">Nephrotic syndrome</span><span class="headingEndMark"> — </span>Marked hyperlipidemia can occur in the nephrotic syndrome due primarily to high serum total and low-density lipoprotein (LDL) cholesterol concentrations. Increased hepatic production of lipoproteins (induced in part by the fall in plasma oncotic pressure) is the major abnormality, but diminished lipoprotein catabolism may play a contributory role. (See  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Chronic renal disease</span><span class="headingEndMark"> — </span>Dyslipidemia is less prominent in chronic kidney disease (CKD), but CKD is associated with elevations in low-density lipoprotein (LDL) cholesterol and triglycerides, and low levels of high-density lipoprotein (HDL) cholesterol; hypertriglyceridemia (type IV hyperlipoproteinemia) occurs in 30 to 50 percent of cases of CKD. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Dyslipidemia'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>Hypothyroidism is frequently associated with and is a common cause of hyperlipidemia. The relationship between hypothyroidism and hyperlipidemia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7857.html" rel="external">"Lipid abnormalities in thyroid disease"</a>.)</p><p>Thus, serum thyrotropin should be measured in all patients with dyslipidemia (see  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a>). Reversal of the hypothyroidism with thyroid hormone replacement leads to correction of the hyperlipidemia.</p><p class="headingAnchor" id="H4278807514"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>Obesity is associated with a number of deleterious changes in lipoprotein metabolism, including high serum concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol, and triglycerides, and a reduction in serum high-density lipoprotein (HDL) cholesterol concentration of about 5 percent [<a href="#rid7">7</a>]. Loss of body fat can reverse the hypercholesterolemia and hypertriglyceridemia. However, improvement in serum total and HDL cholesterol, HDL2 cholesterol, and apolipoprotein A-I is primarily limited to patients with LDL subclass A; improvement occurs in only one-third of patients with LDL subclass B [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Dyslipidemia'</a>.)</p><p class="headingAnchor" id="H1481199198"><span class="h1">LIFESTYLE FACTORS</span></p><p class="headingAnchor" id="H7"><span class="h2">Cigarette smoking</span><span class="headingEndMark"> — </span>Smoking modestly lowers the serum high-density lipoprotein (HDL) cholesterol concentrations and may induce insulin resistance [<a href="#rid9">9-11</a>]. In the screening phase of the <a class="drug drug_general" data-topicid="8696" href="/z/d/drug information/8696.html" rel="external">Bezafibrate</a> Infarction Prevention Study Group, for example, the mean serum HDL cholesterol concentration was 40 mg/dL (1 mmol/L) in nonsmokers, 37 mg/dL (1 mmol/L) in former smokers, and 35 mg/dL (1 mmol/L) in current smokers with an intake of two packs per day or more [<a href="#rid10">10</a>]. Another report found that the effect of smoking was more prominent if adjusted for concomitant alcohol intake; in such patients, smoking was associated with a 5 to 9 mg/dL (0.1 to 0.2 mmol/L) decline in serum HDL cholesterol [<a href="#rid11">11</a>]. These effects are reversible within one to two months after smoking cessation [<a href="#rid12">12-14</a>]. In addition, cigarette smoking impairs HDL function by reducing antioxidant and antiinflammatory capacity and impeding cellular cholesterol efflux [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a>.)</p><p class="headingAnchor" id="H3449716745"><span class="h2">Excessive alcohol consumption</span><span class="headingEndMark"> — </span>While moderate alcohol consumption generally has favorable effects on lipids (see  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>), excessive alcohol consumption can raise triglyceride levels [<a href="#rid16">16,17</a>]. This is a particular concern in patients with severe hypertriglyceridemia at baseline and patients who have had triglyceride-associated acute pancreatitis.</p><p class="headingAnchor" id="H9"><span class="h1">MEDICATIONS</span><span class="headingEndMark"> — </span>Some medications, including thiazide diuretics, beta blockers, and oral estrogens can cause modest changes in serum lipid concentrations (see  <a class="medical medical_review" href="/z/d/html/3867.html" rel="external">"Antihypertensive drugs and lipids"</a> and  <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk"</a> and  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>). Some of the atypical antipsychotic agents, in particular <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, have been associated with weight gain, obesity, hypertriglyceridemia, and development of diabetes mellitus [<a href="#rid18">18-21</a>]. The mechanism(s) by which they cause the metabolic syndrome have not been defined.</p><p>Antiretroviral regimens used for human immunodeficiency virus (HIV) infection, and in particular the protease inhibitors, have been associated with abnormalities in lipids and glucose metabolism often as part of a lipodystrophy syndrome. (See  <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">"Lipodystrophic syndromes", section on 'Lipodystrophy associated with HIV therapy'</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3440.html" rel="external">"Patient education: High cholesterol and lipids (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1741.html" rel="external">"Patient education: Preventing complications from diabetes (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3433.html" rel="external">"Patient education: High cholesterol and lipid treatment options (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H655288727"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – In many patients, hyperlipidemia may be caused by some "nonlipid" etiology  (<a class="graphic graphic_table graphicRef114879" href="/z/d/graphic/114879.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease associations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes – In patients with type 2 diabetes mellitus, hyperlipidemia occurs in association with insulin resistance and frequently involves increased triglycerides and low serum high-density lipoprotein (HDL) cholesterol. (See <a class="local">'Diabetes mellitus'</a> above and  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Lipid management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease – Primary biliary cholangitis and similar disorders may be accompanied by marked hypercholesterolemia that results from an accumulation of lipoprotein-X and lipoprotein-Z. (See <a class="local">'Cholestatic liver disease'</a> above and  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal diseases</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Nephrotic syndrome – Marked hyperlipidemia can occur in the nephrotic syndrome due primarily to high serum total and low-density lipoprotein (LDL) cholesterol concentrations. (See <a class="local">'Nephrotic syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Chronic kidney disease (CKD) – Dyslipidemia is less prominent in CKD, but CKD is associated with elevations in LDL cholesterol and triglycerides, and low levels of HDL cholesterol; hypertriglyceridemia (type IV hyperlipoproteinemia) occurs in 30 to 50 percent of cases of CKD. (See <a class="local">'Chronic renal disease'</a> above and  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Dyslipidemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypothyroidism – This is a common cause of hyperlipidemia, most typically raising LDL cholesterol, but hypertriglyceridemia can also be seen. We advise screening for hypothyroidism in all patients with dyslipidemia. (See <a class="local">'Hypothyroidism'</a> above and  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obesity is associated with a number of deleterious changes in lipid metabolism, including high serum concentrations of total cholesterol, LDL cholesterol, very low-density lipoprotein (VLDL) cholesterol, and triglycerides, and a reduction in serum HDL cholesterol concentration. (See <a class="local">'Obesity'</a> above and  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Dyslipidemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cigarette smoking modestly lowers the serum HDL cholesterol concentrations and HDL atheroprotective properties. (See <a class="local">'Cigarette smoking'</a> above and  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Excessive alcohol consumption can raise triglyceride levels. (See <a class="local">'Excessive alcohol consumption'</a> above and  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – A number of medications can affect serum lipid concentrations, either directly or through effects on weight or glucose metabolism. (See <a class="local">'Medications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol 2012; 110:823.</a></li><li><a class="nounderline abstract_t">Zavaroni I, Dall'Aglio E, Alpi O, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis 1985; 55:259.</a></li><li><a class="nounderline abstract_t">Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723.</a></li><li><a class="nounderline abstract_t">Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52:453.</a></li><li><a class="nounderline abstract_t">Waksman O, Cho DJ, Kim H, et al. Lipoprotein-X and Lipoprotein-Z Induced Hyperviscosity Syndrome in the Setting of Cholestatic Liver Failure. JACC Case Rep 2022; 4:1348.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98:1351.</a></li><li><a class="nounderline abstract_t">Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.</a></li><li><a class="nounderline abstract_t">Katzel LI, Coon PJ, Rogus E, et al. Persistence of low HDL-C levels after weight reduction in older men with small LDL particles. Arterioscler Thromb Vasc Biol 1995; 15:299.</a></li><li><a class="nounderline abstract_t">Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992; 339:1128.</a></li><li><a class="nounderline abstract_t">Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992; 86:839.</a></li><li><a class="nounderline abstract_t">Criqui MH, Cowan LD, Tyroler HA, et al. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results form the Lipid Research Clinics Follow-up Study. Am J Epidemiol 1987; 126:629.</a></li><li><a class="nounderline abstract_t">Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis 1988; 74:85.</a></li><li><a class="nounderline abstract_t">Nilsson P, Lundgren H, Söderström M, et al. Effects of smoking cessation on insulin and cardiovascular risk factors--a controlled study of 4 months' duration. J Intern Med 1996; 240:189.</a></li><li><a class="nounderline abstract_t">Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994; 97:242.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016; 13:48.</a></li><li><a class="nounderline abstract_t">Wakabayashi I. Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus. Alcohol Alcohol 2011; 46:301.</a></li><li><a class="nounderline abstract_t">Park H, Kim K. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol 2012; 47:282.</a></li><li><a class="nounderline abstract_t">Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24:453.</a></li><li><a class="nounderline abstract_t">Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767.</a></li><li><a class="nounderline abstract_t">Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157:975.</a></li><li><a class="nounderline abstract_t">Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl 23:39.</a></li></ol></div><div id="topicVersionRevision">Topic 4568 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658245" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Secondary causes of dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893447" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2374275" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12540621" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36299645" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lipoprotein-X and Lipoprotein-Z Induced Hyperviscosity Syndrome in the Setting of Cholestatic Liver Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323525" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219830" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7749838" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Persistence of low HDL-C levels after weight reduction in older men with small LDL particles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349365" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Insulin resistance and cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516196" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631053" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results form the Lipid Research Clinics Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3214483" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918509" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of smoking cessation on insulin and cardiovascular risk factors--a controlled study of 4 months' duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092173" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Changes in cardiovascular risk profile during the cessation of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323267" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dysfunctional HDL and atherosclerotic cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330295" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371847" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association of alcohol consumption with lipid profile in hypertensive men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586536" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584766" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Olanzapine increases weight and serum triglyceride levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831479" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603884" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
